Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Abstract readClinical Trial, Phase IIIComparative StudyRandomized Controlled Trial
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 143 papers, 9 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed, 9 pooled it
9.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
143 citing papers in PubMed, 9 syntheses or guidelines pooled it, 283 citations in OpenAlex.
- The impact of menopausal status on the efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: a systematic review and meta-analysis of phase III clinical trials.Breast cancer research and treatment · 2026Pooled it
- The impact of hyperglycaemia and/or type 2 diabetes on women with breast cancer undergoing or post-cytotoxic chemotherapy: a systematic literature review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025.Current oncology (Toronto, Ont.) · 2026Guideline
- The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer-A Systematic Review and Meta-Analysis.Current oncology (Toronto, Ont.) · 2024Pooled it
- Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.Lancet (London, England) · 2023Pooled it
- Current perspectives and trends in nanoparticle drug delivery systems in breast cancer: bibliometric analysis and review.Frontiers in bioengineering and biotechnology · 2023Pooled it
- The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.BMC cancer · 2021Pooled it
- Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.BMC cancer · 2019Pooled it
- Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer: A systematic review and meta-analysis.Medicine · 2018Pooled it
- A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer.Breast cancer research and treatment · 2024Trial
- Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.Breast cancer research and treatment · 2020Trial
- Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.Clinical breast cancer · 2019Trial
- Trial
- Comparison of chemotherapeutic combination therapy, dosing frequency and dosing sequence for the adjuvant treatment of early-stage breast cancer: a network meta-analysis.Annals of medicine · 2026Article
- [Anthracycline use in breast cancer based on our current knowledge].Magyar onkologia · 2026Review
- Prediction of Anthracycline Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study.JCO precision oncology · 2026Article
- Adaptive and sequential cancer therapies emerge from treatment schedule optimization.Research square · 2026Article
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025.Current oncology (Toronto, Ont.) · 2026Article
- Meta-analysis of genome-wide association studies of doxorubicin-induced arrhythmia identifiesmedRxiv : the preprint server for health sciences · 2025Article
83 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 1 institution in 1 country.
Joanne L BlumJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Patrick J FlynnJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Greg YothersJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Lina AsmarJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Charles E GeyerJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Samuel A JacobsJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Nicholas J RobertJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Judith O HopkinsJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Joyce A O'ShaughnessyJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Chau T DangJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Henry Leonidas GómezJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Louis FehrenbacherJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Svetislava J VukeljaJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Alan P LyssJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Devchand PaulJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Adam M BrufskyJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Jong-Hyeon JeongJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Linda H ColangeloJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Sandra M SwainJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Eleftherios P MamounasJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Stephen E JonesJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Norman WolmarkJoanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.
Texas Oncology · US
Funding
NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8MStatistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI James J. Dignam, GREG YOTHERS · 2014 to 2026
$146.4MNRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5MNCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS UG1 CA189867
Abstract
Purpose Docetaxel and cyclophosphamide (TC) was superior to doxorubicin and cyclophosphamide (AC) in a trial in early breast cancer. However, activity of TC relative to AC regimens with a taxane (TaxAC) is unknown. Methods In a series of three adjuvant trials, women were randomly assigned to TC for six cycles (TC6) or to a standard TaxAC regimen. US Oncology Research (USOR) 06-090 compared TC6 with docetaxel, doxorubicin, and cyclophosphamide (TAC6). National Surgical Adjuvant Breast and Bowel Project (NSABP) B-46-I/USOR 07132 compared TC6, TAC6, or TC6 plus bevacizumab. NSABP B-49 compared TC6 with several standard AC and taxane combination regimens. Before any analysis of individual trials, a joint efficacy analysis of TC versus the TaxAC regimens was planned, with invasive disease-free survival (IDFS) as the primary end point. Patients who received TC6 plus bevacizumab on NSABP B-46-I/USOR 07132 were not included. A hazard ratio (HR) from a stratified Cox model that exceeded 1.18 for TC6 versus TaxAC was predefined as inferiority for TC6. The prespecified interim monitoring plan was to report for futility if the HR was > 1.18 when 334 IDFS events were observed (50% of 668 events required for definitive analysis). Results A total of 2,125 patients were randomly assigned to receive TC6 regimens and 2,117 patients were randomly assigned to receive TaxAC regimens. The median follow-up time was 3.3 years. There were 334 IDFS events, and the HR for TC6 versus TaxAC was 1.202 (95% CI, 0.97 to 1.49), which triggered early reporting for futility. The 4-year IDFS was 88.2% for TC6 and was 90.7% for TaxAC ( P = .04). Tests for treatment interaction by protocol, hormone receptor status, and nodal status were negative. Conclusion The TaxAC regimens improved IDFS in patients with high-risk human epidermal growth factor receptor 2-negative breast cancer compared with the TC6 regimen.
Indexed as
AnthracyclinesAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsBridged-Ring CompoundsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingChemotherapy, AdjuvantCyclophosphamideDisease-Free SurvivalDocetaxelDoxorubicinErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansLymphatic MetastasisAnthracyclinesBridged-Ring CompoundsCyclophosphamideDocetaxelDoxorubicinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteronetaxaneTaxoids
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.